Skip to main content
Premium Trial:

Request an Annual Quote

Michael Cosgrove, Robert Saltmarsh, and Michael Nemzek

Premium

Michael Cosgrove, formerly director of enterprise systems at image informatics firm Scimagix, has left the company, according to BioInform, an Inside Bioassays sister publication. Scimagix was acquired by image analysis software firm BioImagene in November. Cosgrove said he is “currently exploring other opportunities within the bioinformatics arena.”


Robert Saltmarsh has been promoted to chief financial officer of Nanogen, the San Diego-based company said last week.

Saltmarsh joined Nanogen as vice president of corporate development in September. Most recently, he was a consultant for several start-up companies and taught entrepreneurial finance at the University of California at Riverside. Saltmarsh holds a BA in economics and an MBA in finance from the University of Michigan.


Michael Nemzek joined Velocity11 of Menlo Park, Calif., as vice president of marketing, the company said last week. Nemzek previously was general manager of discovery tools at Symyx Technologies. Prior to that, Nemzek was an executive with Cellomics; Genosys Biotechnologies (now part of Sigma-Aldrich); Tropix (now part of Applied Biosystems); and EG&G (now part of PerkinElmer). Velocity11 develops automation technologies for pharma/biotech and genomics labs.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.